Ignacio Portales-Castillo, Daniela Kroshinksy, Cindy K Malhotra, Roberta Culbert-Costley, Mario Gennaro Cozzolino, Shelly Karparis, Charles L Halasz, Jeremy Goverman, Harold J Manley, Rajeev Malhotra, Sagar U Nigwekar
Calciphylaxis is a rare but devastating disease with a mortality rate up to 50% in 1 year. It is characterized by profoundly painful ischemic skin lesions and vascular calcification that affects predominantly patients with end stage renal disease. The use of certain medications is an important modifiable risk factor in calciphylaxis and discontinuation of these is a mainstay of treatment. Areas Covered: This review will provide an overview of calciphylaxis and will focus on how certain therapeutic agents can affect the risk of calcification and associated thrombosis, key processes involved in the development of calciphylaxis...
December 21, 2018: Expert Opinion on Drug Safety